Symeres

Symeres will be present at BioEurope 2024 from Nov 4-6, 2024 in Stockholm, Sweden. Our team consisting of Sascha Hartmann, Norimasa Morita, and Ana Rioz are excited to meet you! Come learn how our organic chemistry expertise can benefit you from early drug discovery to manufacturing needs.   This important event celebrates 30 years of facilitating partnerships with 5,500 attendees representing more than 2,800 companies from different countries. BioEurope offers many opportunities to partner, network and gain unique industry insights within biotech innovation, trends and challenges/opportunities within the life sciences.   Symeres looks forward to seeing previous and current collaborators, as well as meeting new ones! If you are interested in meeting us, please feel free to connect over Linkedln to arrange a meeting or get in touch with us at the event. #bioeurope #partnerships #collaborations #industry

We were excited to host a large group of chemistry students that visited Symeres at one of our Netherlands sites hosted by the Royal Netherlands Chemical Society (Koninklijke Nederlandse Chemische Vereniging-KNCV). The students participated in a brainstorming session to discuss activities that could better support young chemists. Then, they were given a tour of the laboratories and a presentation about the work done at Symeres to teach them more about the chemical industry. Thank you to Marieke Beemsterboer and the team for their hard work in organizing and facilitating a great day! We were happy to have the opportunity to connect with these young scientists and look forward to maybe seeing them in the future. #kncv #connections #visits #chemistry  

Symeres and Admescope will be present at Discovery US 2024 on Nov 7-8th in Boston, MA. Come meet our team Leah Haydock, Miia Kovalainen and Chris Teleha and discuss how we can support your research projects with our expertise in biology and chemistry for small molecule drug discovery! We look forward to seeing you there. #event #network #collaboration #drugdiscovery

Danicopan, ceftobiprole, pegulicianine, tovorafenib, mavorixafor, sofpironium bromide, deuruxolitinib, vorasidenib, and seladelpar have these three things in common: ·       These drugs were approved by the FDA this year. ·       These drugs have an important impact on society. ·       They all have chiral centers. For many years, over 50% of approved 𝐝𝐫𝐮𝐠𝐬 have 𝐜𝐡𝐢𝐫𝐚𝐥 𝐜𝐞𝐧𝐭𝐞𝐫𝐬. Creating a single enantiomer is often one of the most challenging steps in organic synthesis. At Symeres, we thrive on such challenges — and are recognized as world-class experts in the field of chirality. Take a look at a snapshot of our introductory presentation, which opens the door to how we can help produce chiral molecules for you. 𝐈𝐧𝐭𝐞𝐫𝐞𝐬𝐭𝐞𝐝? Contact our specialists here: https://lnkd.in/daJEr7Dq

On Friday, we celebrated some of our colleagues with the longest 'half-life' of our company - 25th work anniversaries with Symeres. We thank you all kindly for all of your hard work, dedication and invaluable contributions to the organization throughout the years. It was a true joy to celebrate such a milestone with you all - Peter Molenveld, Ruben Leenders, Sander Schrievers, sjoerd aertssen, Eddy Damen and Dirk Vandenput. The day was filled with laughter and nostalgia as we enjoyed the ‘frietkraam’ (fry truck) and reminisced over the many fond memories shared among colleagues. We are deeply grateful for our seasoned scientists who have been part of Symeres from the beginning. Your continued commitment shapes who we are today, along with many of our other longstanding colleagues. #workanniversary #longhalflife #seasoned #frietkraam

𝐓𝐨𝐧 𝐕𝐫𝐢𝐞𝐬 𝐀𝐰𝐚𝐫𝐝 2024:   Symeres is excited to share that we celebrated our internal annually awarded Ton Vries award. This award is named after one of our chemists that greatly contributed to the foundations that made Symeres what it is today.   The competition was quite fierce this year with teams in the US and Europe that submitted their very best work to be considered for this award. The criteria was focused on projects that were collaborative between different sites and interdisciplinary teams within Symeres, along with consideration for the overall technical difficulty, as well as success of the project itself. With so many outstanding chemistry projects and brilliant work showcased, choosing a winner was no easy task!   The winner of the Ton Vries 2024 award went to the team of Maris Vilums and our finalist teams had presentations given by Bart Saes, Erik de Heuvel, Paul Werkhoven, Vishnu Damalanka and Sander van Assema. Furthermore, we appreciate the participation of Tommi Meulemans and Jim van Wiltenburg too. Congratulations to all those who were involved that made these projects a rousing success!   This innovative chemistry exemplifies the heart of Symeres, and we owe these remarkable scientific achievements to the collaboration and expertise of our talented scientists.

𝐓𝐡𝐞 𝐍𝐨𝐛𝐞𝐥 𝐏𝐫𝐢𝐳𝐞 𝐢𝐧 𝐂𝐡𝐞𝐦𝐢𝐬𝐭𝐫𝐲 2024 was recently awarded for breakthroughs in deciphering the code of proteins and determining their structure! This prestigious honor went to David Baker, recognized for his 2003 research into creatively using amino acids to design novel proteins that were once thought impossible to make. His work has had remarkable applications in vaccines, pharmaceuticals, and more. Additionally, John Jumper and Demis Hassabis were awarded for their creation of AlphaFold2, an AI model capable of predicting the structures of over 200 million proteins identified so far. AlphaFold2 has been adopted globally by more than 2 million users, helping scientists investigate novel protein structures for various applications, including enzymes that can break down plastic. Together, their work marks a significant leap forward in our understanding of proteins and their future potential. At Symeres, we are also leaders in 𝐜𝐨𝐦𝐩𝐮𝐭𝐚𝐭𝐢𝐨𝐧𝐚𝐥 𝐜𝐡𝐞𝐦𝐢𝐬𝐭𝐫𝐲, 𝐨𝐟𝐟𝐞𝐫𝐢𝐧𝐠 𝐭𝐚𝐢𝐥𝐨𝐫-𝐦𝐚𝐝𝐞 𝐚𝐩𝐩𝐫𝐨𝐚𝐜𝐡𝐞𝐬 𝐭𝐨 𝐦𝐞𝐞𝐭 𝐨𝐮𝐫 𝐜𝐥𝐢𝐞𝐧𝐭𝐬' 𝐧𝐞𝐞𝐝𝐬. Molecular modeling is an integrated part of our medicinal chemistry projects, but we also offer it as a stand-alone service. To learn more about how we approach computational medicinal chemistry, check out our 𝐢𝐧𝐭𝐞𝐫𝐯𝐢𝐞𝐰 𝐰𝐢𝐭𝐡 𝐨𝐮𝐫 𝐂𝐨𝐦𝐩𝐮𝐭𝐞𝐫-𝐀𝐢𝐝𝐞𝐝 𝐃𝐫𝐮𝐠 𝐃𝐞𝐬𝐢𝐠𝐧 (𝐂𝐀𝐃𝐃) 𝐃𝐞𝐩𝐚𝐫𝐭𝐦𝐞𝐧𝐭: https://lnkd.in/e8iZpXEv #NobelPrizeChemistry #ComputationalChemistry #AI #PredictionModels #MolecularModeling

Meet the Symeres team at BOS Manchester 2024 from November 27-28 in Manchester, UK with Roger McDonald. With over 30 years of experience in small molecules, we look forward to discussing how we can support your drug discovery and development programs. Symeres offers a full range of integrated services, from hit finding to pre(clinical) research formulation. Biotech Outsourcing Strategies (BOS) Manchester aims to bring together stakeholders in R&D outsourcing to share experiences and facilitate business partnerships. Are you interested in arranging a meeting during the event to learn more about how Symeres can collaborate with you? Please schedule one with Roger McDonald. We look forward to reconnecting with our partners and forging new connections as well. See you there! #bosmanchester2024 #biopharma #biotech #cro #networking

Join the Symeres Team at the Pharma Partnering Summit 2024! We’re excited to announce that Symeres will be attending the Pharma Partnering Summit 2024, taking place from October 16-17th in Boston, MA. Our team, including Rory Curtis, Paul O'Shea and Russell Thomas, will be present, and we invite you to meet with us to discuss how we can support your drug discovery and development programs. Additionally, Paul O'Shea will be delivering a presentation titled: "The Role of CMC in IND Enabling Studies" 🗓 Date: October 16th, 2024 🕒 Time: 9:30 AM This summit brings together senior executives and decision-makers from across the globe to connect, explore new opportunities, and foster meaningful collaborations. We look forward to engaging with you during showcases, meetings, and networking sessions! #collaborations #fundraising #commercial #networking #pharmapartneringsummit

𝗖𝘂𝗿𝗶𝗼𝘂𝘀 𝘁𝗼 𝗸𝗻𝗼𝘄 𝗵𝗼𝘄 𝗺𝗶𝗥𝗡𝗔 𝗮𝗻𝗱 𝗹𝗶𝗽𝗶𝗱𝘀 𝗮𝗿𝗲 𝗰𝗼𝗻𝗻𝗲𝗰𝘁𝗲𝗱? The Nobel Prize in Medicine was recently awarded to Victor Ambros and Gary Ruvkun for their discovery of microRNA (miRNA), crucial for regulating genetic activity. miRNAs are small RNA molecules that bind to messenger RNA (mRNA), inhibiting protein synthesis or degradation. Even though all cells in the body contain identical DNA, it is through this mechanism that there are diverse cell types. miRNAs are also being explored as cancer therapies, functioning as tumor suppressors. Research is focused on safely delivering miRNA or mRNA using lipid nanoparticles, which enhance stability, intracellular delivery, better targeting and dose reduction. At Symeres, in conjunction with Organix, we specialize in: 1) Experience with MC3, a gold standard in ionizable lipids. 2) Production of cationic lipids, lipopeptides, lipoids, biodegradable lipids, arachidonyl lipids, and GalNAc derivatives. 3) Lipid scale-up capabilities, including GMP-compliant processes and the production of microspheres. Symeres has been supporting the global pharma and biotech industry with the synthesis and (ultra)purification of these novel lipids, such as those used in lipid nanoparticles used to deliver RNA-based therapeutics. #NobelPrize #Chemistry #𝗺𝗶𝗥𝗡𝗔 #Lipids #Symeres #CRO Learn more here: https://lnkd.in/eDbWcSrr